How were (BIOA)'s earnings last quarter?

(BIOA) (NYSE:BIOA) posted its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.02. The biotechnology company had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.37 million.

What other stocks do shareholders of (BIOA) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (BIOA) investors own include ProQR Therapeutics (PRQR) , Flexion Therapeutics (FLXN) , Rite Aid (RAD) , LadRx (CYTR) , Intellipharmaceutics International (IPCIF) , Biopharmx (BPMX) , EyePoint Pharmaceuticals (EYPT) , MoneyGram International (MGI) , AbbVie (ABBV) and Aurinia Pharmaceuticals (AUPH) .

NYSE:BIOA

(BIOA) (BIOA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BIOA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $0.01
▼
$0.03
50-Day Range: N/A
52-Week Range: $0.01
▼
$2.88

Volume: 15.51 million shs
Average Volume: 2.97 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get (BIOA) alerts:

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About (BIOA) Stock (NYSE:BIOA)

BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

BIOA Stock News Headlines

April 16, 2024 | finanznachrichten.de

The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB

April 12, 2024 | morningstar.com

Camurus AB CAMX

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

April 10, 2024 | finance.yahoo.com

BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm

April 6, 2024 | finance.yahoo.com

B Jun 2024 50.000 call

April 6, 2024 | finance.yahoo.com

B Sep 2024 40.000 put

April 6, 2024 | finance.yahoo.com

B Sep 2024 30.000 put

April 1, 2024 | finance.yahoo.com

Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 22, 2024 | finance.yahoo.com

Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons

March 16, 2024 | finance.yahoo.com

B Apr 2024 30.000 put

March 16, 2024 | finance.yahoo.com

B Apr 2024 40.000 call

March 16, 2024 | finance.yahoo.com

B Apr 2024 45.000 call

March 11, 2024 | finance.yahoo.com

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

March 7, 2024 | finance.yahoo.com

BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

February 29, 2024 | finanznachrichten.de

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD congress

February 29, 2024 | finance.yahoo.com

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

February 17, 2024 | morningstar.com

Bioiasis AD BIOA

February 6, 2024 | finanznachrichten.de

BioArctic: Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023

February 6, 2024 | finance.yahoo.com

Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023

January 11, 2024 | finance.yahoo.com

The European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic

January 9, 2024 | finanznachrichten.de

BioArctic: Leqembi® approved for the treatment of Alzheimer's disease in China

January 9, 2024 | finance.yahoo.com

Leqembi® approved for the treatment of Alzheimer's disease in China

December 13, 2023 | finance.yahoo.com

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

December 12, 2023 | finanznachrichten.de

BioArctic: LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

December 8, 2023 | finance.yahoo.com

BioArctic AB (publ) (BIOA-B.ST)

November 22, 2023 | morningstar.com

BioArctic AB Class B BIOA B

See More Headlines

Receive BIOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (BIOA) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2016
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NYSE:BIOA
CUSIP: N/A
CIK: 1534287
Web: www.bio-amber.com
Phone: +1-612-7474423
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Raymond J. Land (Age 72)
Chairman of the Board
Richard P. Eno
Chief Financial Officer, Director
Mario Settino
Chief Financial Officer
Michael A. Hartmann (Age 48)
Executive Vice President
James Millis (Age 59)
Chief Technology Officer
Robert Frost
Director
Kurt W. Briner (Age 70)
Independent Director
Heinz Haller (Age 62)
Independent Director
Ellen B. Richstone (Age 65)
Independent Director
Kenneth W Wall (Age 66)
Independent Director

BIOA Stock Analysis - Frequently Asked Questions

How were (BIOA)'s earnings last quarter?: (BIOA) (NYSE:BIOA) posted its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.02. The biotechnology company had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.37 million.
What other stocks do shareholders of (BIOA) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other (BIOA) investors own include ProQR Therapeutics (PRQR), Flexion Therapeutics (FLXN), Rite Aid (RAD), LadRx (CYTR), Intellipharmaceutics International (IPCIF), Biopharmx (BPMX), EyePoint Pharmaceuticals (EYPT), MoneyGram International (MGI), AbbVie (ABBV) and Aurinia Pharmaceuticals (AUPH).

This page (NYSE:BIOA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

(BIOA) (BIOA) Stock Price, News & Analysis

About (BIOA) Stock (NYSE:BIOA)

BIOA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

BIOA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info